SG10202107836SA - Hyperstabilized liposomes increase targeting of mitotic cells - Google Patents

Hyperstabilized liposomes increase targeting of mitotic cells

Info

Publication number
SG10202107836SA
SG10202107836SA SG10202107836SA SG10202107836SA SG10202107836SA SG 10202107836S A SG10202107836S A SG 10202107836SA SG 10202107836S A SG10202107836S A SG 10202107836SA SG 10202107836S A SG10202107836S A SG 10202107836SA SG 10202107836S A SG10202107836S A SG 10202107836SA
Authority
SG
Singapore
Prior art keywords
hyperstabilized
mitotic cells
increase targeting
liposomes increase
liposomes
Prior art date
Application number
SG10202107836SA
Other languages
English (en)
Inventor
Chang Zhi Adrian Ng
Shen-Yi Ian Cheong
Original Assignee
Temasek Life Sciences Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Ltd filed Critical Temasek Life Sciences Laboratory Ltd
Publication of SG10202107836SA publication Critical patent/SG10202107836SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202107836SA 2017-01-18 2018-01-17 Hyperstabilized liposomes increase targeting of mitotic cells SG10202107836SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762447498P 2017-01-18 2017-01-18

Publications (1)

Publication Number Publication Date
SG10202107836SA true SG10202107836SA (en) 2021-08-30

Family

ID=62909275

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906539YA SG11201906539YA (en) 2017-01-18 2018-01-17 Hyperstabilized liposomes increase targeting of mitotic cells
SG10202107836SA SG10202107836SA (en) 2017-01-18 2018-01-17 Hyperstabilized liposomes increase targeting of mitotic cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201906539YA SG11201906539YA (en) 2017-01-18 2018-01-17 Hyperstabilized liposomes increase targeting of mitotic cells

Country Status (18)

Country Link
US (1) US11331272B2 (he)
EP (1) EP3570818B1 (he)
JP (2) JP7232530B2 (he)
KR (1) KR20190122676A (he)
CN (1) CN110381922A (he)
AU (1) AU2018210748B2 (he)
BR (1) BR112019014718A2 (he)
CA (1) CA3050686A1 (he)
CL (1) CL2019002002A1 (he)
CO (1) CO2019008876A2 (he)
IL (1) IL268099B2 (he)
MA (1) MA47319A (he)
MX (1) MX2019008533A (he)
PH (1) PH12019501650A1 (he)
RU (1) RU2765736C2 (he)
SG (2) SG11201906539YA (he)
TW (1) TWI816656B (he)
WO (1) WO2018136002A1 (he)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
EP1429726A2 (en) 2001-09-06 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
EP1746976B1 (en) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
JP5057362B2 (ja) 2004-11-02 2012-10-24 国立大学法人 東京医科歯科大学 リポソーム及びこれを用いた細胞に対する物質注入方法
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术(石家庄)有限公司 一种脂质体药物及其制备方法
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US20090285881A1 (en) * 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
ES2568778T3 (es) 2009-04-17 2016-05-04 3M Innovative Properties Company Lámina de protección contra rayos con conductor estampado
US9220682B2 (en) * 2009-04-22 2015-12-29 Emory University Nanocarrier therapy for treating invasive tumors
WO2010143972A2 (en) 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
EP2773426B1 (en) * 2011-10-31 2018-08-22 Mallinckrodt LLC Combinational liposome compositions for cancer therapy
DK2950784T3 (da) * 2013-02-01 2021-07-05 Zoneone Pharma Inc Fjernladning af svagt vandopløselige lægemidler i liposomer
WO2014160337A1 (en) * 2013-03-13 2014-10-02 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
KR101925507B1 (ko) 2013-03-15 2018-12-05 타이완 리포솜 캄퍼니 리미티드 조절 약물 방출 리포솜 조성물
CN106659683A (zh) * 2014-01-14 2017-05-10 约翰斯·霍普金斯大学 包封修饰的环糊精复合物的脂质体组合物及其应用
EP3131587A4 (en) * 2014-04-14 2017-11-01 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
US20160175250A1 (en) * 2014-12-23 2016-06-23 Tolmar Inc. Method for Making Liposomes Containing an Active Pharmaceutical Ingredient
JP2018505224A (ja) 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーOP Nano Co.,Ltd. ナノ粒子を含む組成物並びに腫瘍を治療する方法

Also Published As

Publication number Publication date
AU2018210748B2 (en) 2023-09-28
RU2019125724A (ru) 2021-02-19
MX2019008533A (es) 2019-12-02
JP7232530B2 (ja) 2023-03-03
BR112019014718A2 (pt) 2020-03-10
TWI816656B (zh) 2023-10-01
RU2765736C2 (ru) 2022-02-02
JP2023002702A (ja) 2023-01-10
PH12019501650A1 (en) 2020-02-24
JP2020505451A (ja) 2020-02-20
IL268099B1 (he) 2024-01-01
WO2018136002A1 (en) 2018-07-26
EP3570818A4 (en) 2020-11-18
CN110381922A (zh) 2019-10-25
KR20190122676A (ko) 2019-10-30
EP3570818B1 (en) 2023-11-01
IL268099A (he) 2019-09-26
US20190358161A1 (en) 2019-11-28
IL268099B2 (he) 2024-05-01
EP3570818A1 (en) 2019-11-27
AU2018210748A1 (en) 2019-08-29
CL2019002002A1 (es) 2020-01-17
SG11201906539YA (en) 2019-08-27
TW201828925A (zh) 2018-08-16
US11331272B2 (en) 2022-05-17
RU2019125724A3 (he) 2021-03-04
CO2019008876A2 (es) 2020-01-17
CA3050686A1 (en) 2018-07-26
MA47319A (fr) 2019-11-27

Similar Documents

Publication Publication Date Title
IL287033A (he) ויסות של ביטוי גן מתווך נוקליאז
IL267378A (he) מערכת ליצירת תרסיס עם זוגות של אלקטרודות
GB2600865B (en) Beamforming of harmonics
IL274179A (he) החלפה מיועדת של קולטני תא t אנדוגניים
IL291055A (he) פורמולציות יציבות של ליפידים וליפוזומים
HK1248740A1 (zh) 低排放聚氨酯的生產
IL285422A (he) שינויים מבוססי טרנספוסון של תאים אימוניים
GB201504320D0 (en) Forming of battery components
EP3411081A4 (en) REGULATION OF GENE EXPRESSION BY APTAM-MODULATED POLYADENYLATION
ZA201707735B (en) Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes
SG10201912370RA (en) PROMOTER OF Hspa5 GENE
IL268099A (he) ליפוזומים היפר-מיוצבים המגדילים מיקוד של תאים מיטוטים
EP3230259A4 (en) Anti-fungals targeting the synthesis of fungal shingolipids
GB201919175D0 (en) Cyclopenta[d[pyrimidines and substituted cyclopenta[d[pyrimidines as antitubulin and microtubule targeting agents
EP3727359C0 (en) TREATMENT OF FIBROSIS WITH INOSITOL
GB201803484D0 (en) Improvements relating to the manufacture of inserts
IL252302A0 (he) תכשירים של פוספוליפידים לשיפור מיומנויות תקשורת
TWM533066U (en) Improved structure of soil
TWM532771U (en) Receiving structure of handbag
TWM534453U (en) Improved structure of power connector
TWM533813U (en) Structure improvement of cover type connector
TWM534078U (en) Buckle structure improvement of box
GB201506427D0 (en) Raven Genetic Enhancement
TWM476648U (en) Improved structure of electric agricultural sprayer
GB201405160D0 (en) International convergence of Bernard's theory